-- Earnings Flash (SESN) SESEN BIO Reports Q2 Loss $-0.16
8:01AM ET 8/08/2022 MT Newswires...
Quotes Snapshot > SESN
Sesen Bio Inc SESN:NASDAQ
Last Price$0.70NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change-0.004(0.55%)
Bid (Size)$0.70 (5)
Ask (Size)$0.71 (6)
Day Low / High$0.69 - 0.72
Volume1.2 M
Read more news Recent News
Sesen Bio Pauses Clinical Trial of Non-Muscle Invasive Bladder Cancer Therapy in US
8:10AM ET 7/18/2022 MT NewswiresSesen Bio (SESN) said Monday it has paused the clinical development of Vicineum, its therapeutic candidate for non-muscle invasive bladder cancer, in the...
Sesen Bio Nixes Reverse Stock Split Plan; Shares Rise
11:04AM ET 6/17/2022 MT NewswiresSesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...
View all Commentary and Analysis
VERU's Shares Jump on Successful COVID-19 Study Results
10:44AM ET 7/08/2022 ZacksVERU gains on the success of its late stage study evaluating the efficacy and safety of oral...
Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
12:56PM ET 6/02/2022 Seeking AlphaThe State Of Biotech In 2022
4:04AM ET 1/03/2022 Seeking AlphaSesen Bio: Interesting Price Drop After CRL
3:10PM ET 11/24/2021 Seeking AlphaCompany Profile
Business DescriptionSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 245 First Street Cambridge, Massachusetts 02142 |
| Phone | +1.617.444.8550 |
| Number of Employees | 24 |
| Recent SEC Filing | 08/11/2022 8-K/A |
| President, Chief Executive Officer & Director | Thomas R. Cannell |
| Chief Financial Officer & Treasurer | Monica Forbes |
| Finance Director | Stephanie Vigue |
| Head of Research | Jeannick Cizeau |
Company Highlights
| Price Open | $0.71 |
| Previous Close | $0.70 |
| 52 Week Range | $0.37 - 6.04 |
| Market Capitalization | $139.6 M |
| Shares Outstanding | 199.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/14/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 2.92 |
| Earnings per Share | -$0.13 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | 238.99% |
| Return on Equity | 29.51% |
Analyst Ratings as of 07/09/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |